SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice-Reference-Cited by-同舟云学术

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice

Published:2019-07-09 Issue:5 Volume:10 Page:1595-1622
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Ali Amar, ,Bain Steve,Hicks Debbie,Newland Jones Phillip,Patel Dipesh C.,Evans Marc,Fernando Kevin,James June,Milne Nicola,Viljoen Adie,Wilding John^ORCID

Funder

Napp Pharmaceuticals Limited

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13300-019-0657-8.pdf

Reference109 articles.

1. Wilding J, Fernando K, Milne N, et al. SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice. Diabetes Ther. 2018;9:1757–73.

2. Pantalone KM, Hobbs TM, Wells BJ, et al. Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system. BMJ Open Diabetes Res Care. 2015;3:e000093.

3. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17:83.

4. Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015;3:105–13.

5. World Health Organization. Fact sheets: cardiovascular diseases (CVDs). 2017. Retrieved from: https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials;Diabetes, Obesity and Metabolism;2024-04-11

2. SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review;Diabetes Therapy;2024-04-05

3. A comprehensive review of small-molecule drugs for the treatment of type 2 diabetes mellitus: Synthetic approaches and clinical applications;European Journal of Medicinal Chemistry;2024-03

4. Exploring the causal factor effects of hypothyroidism on ischemic stroke: a two-sample Mendelian randomization study;Frontiers in Neurology;2024-01-31

5. Animal studies of sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease;Annals of Gastroenterology;2024